Table 2 Therapeutic strategy during first-line therapy for mBC disease
HR + /HER2 − (N = 13,283) | TN (N = 2845) | HR + /HER2 + (N = 2502) | HR − /HER2 + (N = 1403) | Total (N = 20,033) | |
|---|---|---|---|---|---|
Chemotherapy only | 1631 (12.3%) | 1804 (63.4%) | 84 (3.4%) | 75 (5.3%) | 3594 (17.9%) |
Targeted therapy only | 8 (0.1%) | 6 (0.2%) | 53 (2.1%) | 116 (8.3%) | 183 (0.9%) |
Endocrine therapy only | 5545 (41.7%) | 39 (1.4%) | 342 (13.7%) | 7 (0.5%) | 5933 (29.6%) |
Chemotherapy and endocrine therapy | 3383 (25.5%) | 46 (1.6%) | 85 (3.4%) | 3 (0.2%) | 3517 (17.6%) |
Chemotherapy and targeted therapy | 699 (5.3%) | 921 (32.4%) | 674 (26.9%) | 1164 (83.0%) | 3458 (17.3%) |
Chemotherapy, targeted therapy and endocrine therapy | 1518 (11.4%) | 15 (0.5%) | 1036 (41.4%) | 33 (2.4%) | 2602 (13.0%) |
Endocrine therapy and targeted therapy | 492 (3.7%) | 1 (0.0%) | 228 (9.1%) | 5 (0.4%) | 726 (3.6%) |
Immunotherapy-based regimen | 6 (0.0%) | 13 (0.5%) | 0 (0.0%) | 0 (0.0%) | 19 (0.1%) |
Other therapy | 1 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (0.0%) |